SCHEMBL2290337

SCHEMBL2290337

CCc1cc(OC)cc(OCC(N)=O)c1-c1nc2ccc(F)cn2c1Nc1c(F)cccc1F

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPA1 O75762 1/20 0.41
CDK4 P11802 2/20 0.36
CDK2 P24941 2/20 0.36
MAPT P10636 2/20 0.35
GAA P10253 1/20 0.35
TPH1 P17752 1/20 0.34
CYP11B1 P15538 1/20 0.34
CYP11B2 P19099 1/20 0.34
PDE10A Q9Y233 1/20 0.34
ATM Q13315 1/20 0.33
PDE4A P27815 1/20 0.33
PDE4B Q07343 1/20 0.33
PDE4C Q08493 1/20 0.33
PDE4D Q08499 1/20 0.33
TP53 P04637 1/20 0.33
ZAP70 P43403 2/20 0.32
KARS1 Q15046 2/20 0.32
TRIM33 Q9UPN9 2/20 0.32
TRIM24 O15164 1/20 0.32
NR1H4 Q96RI1 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2287599 0.93 GAA (0.41) TRPA1MAPTGAACYP11B1CYP11B2
SCHEMBL2295061 0.92 MAPT (0.40) TRPA1MAPTGAATPH1CYP11B1
SCHEMBL2292370 0.91 TRPA1 (0.42) TRPA1CDK4CDK2MAPTGAA
SCHEMBL2287002 0.91 TRPA1 (0.38) TRPA1MAPTGAACYP11B1CYP11B2
SCHEMBL2295321 0.90 GAA (0.39) TRPA1MAPTGAACYP11B1CYP11B2
SCHEMBL2290931 0.88 MAPT (0.38) TRPA1MAPTGAACYP11B1CYP11B2
SCHEMBL2287227 0.88 GAA (0.42) TRPA1MAPTGAATP53
SCHEMBL2290845 0.88 TRIM33 (0.38) TRPA1MAPTGAACYP11B1CYP11B2
SCHEMBL2288201 0.87 GAA (0.41) TRPA1MAPTGAATP53
SCHEMBL2293350 0.86 CNR2 (0.35) TRPA1MAPTGAACYP11B1CYP11B2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP claimed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US claimed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US claimed
EP-2032571-B1 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GMBH (DE) 2014-12-03 EP disclosed
US-8258151-B2 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors MERCK PATENT GMBH (DE) 2012-09-04 US disclosed
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS MERCK PATENT GESELLSCHAFT (DE) 2011-08-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110195991-A1 3-AMINOIMIDAZO [1,2-A] PYRIDINE DERIVATIVES AS SGLT INHIBITORS GLP1R, SLC5A1, SLC5A2 TRPA1 1229/4885CDK4 843/4885CDK2 1200/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.